Drugs / Tyrosinase YMD peptide
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00112229 | Apr 2003 → Aug 2011 | melanoma | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tyrosinase YMD peptide | “Melan-A natural peptide + Tyrosinase YMD peptide + CpG + Montanide” NCT00112229 ↗ |
| Modality | Peptide | “The tumor antigenic peptides Melan-A/Mart-1 (EAA and ELA) and Tyrosinase (YMD)” NCT00112229 ↗ |